Axial T1-weighted (A) and STIR (B) images depict denervation edemalike signal of extensor muscles of dorsal and mobile wad compartments with no fatty infiltration or atrophy consistent with NS-RADS M1.

Neuropathy Score Reporting and Data System (NS-RADS) Subclass M1 (Edemalike Signal): Axial T1-weighted (A) and STIR (B) images depict denervation edemalike signal of extensor muscles of dorsal and mobile wad compartments with no fatty infiltration or atrophy consistent with NS-RADS M1.


March 4, 2022 — According to an article in ARRS’ American Journal of Roentgenology (AJR), a new reporting and data system for standardized evaluation and recording of peripheral nerve pathologies—Neuropathy Score Reporting and Data System (NS-RADS)—has been created and validated in a multicenter study.

“The proposed NS-RADS classification is accurate and reliable across different reader experience levels and a spectrum of peripheral neuropathy conditions,” wrote lead researcher Avneesh Chhabra of UT Southwestern in Dallas, TX. “NS-RADS can be used as a standardized guideline for reporting peripheral neuropathies and improved multidisciplinary communications.”

Chhabra and team’s retrospective study included 100 patients with nerve imaging examinations and known clinical diagnoses. Utilizing mutually agreed-upon qualitative benchmarks for classifying and grading peripheral neuropathies, different classes were established to account for the spectrum of underlying pathologies (unremarkable, injury, neoplasia, entrapment, diffuse neuropathy, not otherwise specified, and postintervention state) with subclasses to describe lesion severity or extent. Validation was performed by 11 fellowship-trained musculoskeletal radiologists across 10 institutions, and after initial multimedia training, all 100 cases were blind-presented to readers.

Offering a uniform lexicon and practical guideline for reporting neuropathic conditions on MRI, ultimately, NS-RADS accuracy for determining milder versus more severe categories per radiologist ranged from 88% to 97% for nerve lesions and from 86% to 94% for muscle abnormalities.

“On the basis of the overall promising interrater agreement shown in this study, we believe that the newly proposed NS-RADS classification will perform as well in routine practice as it did in this initial validation study,” the authors of this AJR article concluded

For more information: arrs.org


Related Content

Feature | Radiology Business | By Melinda Taschetta-Millane

One on One interviews with radiology trailblazers and historic FDA clearances made the top-read list for April. Take a ...

Time May 03, 2024
arrow
Feature | Radiation Dose Management | By Christine Book

Advances in the growing radiation dose management market are continually helping those who administer treatment to focus ...

Time May 03, 2024
arrow
News | Pediatric Imaging

May 2, 2024 — Head and abdominal trauma is a leading cause of death for children. About 1%–2% of children who come to ...

Time May 02, 2024
arrow
Feature | Radiology Business

Beginning this spring, ITN will begin sending out a bi-monthly survey to our readers on a variety of topics, which we ...

Time May 02, 2024
arrow
News | Breast Imaging

May 1, 2024 — After the issuance of updated breast screening recommendations by the U.S. Preventive Services Task Force ...

Time May 01, 2024
arrow
News | Ultrasound Imaging

April 30, 2024 — Best Nomos, a TeamBest Global Company, is launching its most modern, highly innovative Compact SONALIS ...

Time April 30, 2024
arrow
News | FDA

April 29, 2024 — The U.S. Food and Drug Administration (FDA) announced Elekta Instrument AB is recalling Disposable ...

Time April 29, 2024
arrow
News | PET Imaging

April 24, 2024 — A new study from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare ...

Time April 24, 2024
arrow
News | Radiology Business

April 23, 2024 — A diverse writing group, led by authors at the University of Toronto, have developed an approach for ...

Time April 23, 2024
arrow
News | FDA

April 23, 2024 — Royal Philips , a global leader in health technology, today announced its Philips Zenition 30 mobile C ...

Time April 23, 2024
arrow
Subscribe Now